News

The epithelium adapts to compensate for changes in the cornea and these changes can be detected with high sensitivity, reducing both false positives and false negatives in the diagnosis of keratoconus.

The destination of Marco Island, Florida not only serves as an excellent backdrop for this year's Ophthalmology Times® EyeCon 2022 but also provides a unique opportunity for family members to see their ophthalmic loved ones in a professional light.

Anti-VEGF biosimilars may offer a therapeutic alternative to the original biologic because they have the ability to lower the overall therapeutic cost in the management of varied chorioretinal disorders.

Investigators advise an ophthalmologic evaluation at the time of tumor diagnosis to detect early vision loss.

Let us know if you will plan to use biosimilars in your daily practice. The poll will be open until October 10, 2022.

In an attempt to halt the progression of dry AMD and geographic atrophy, the use of high-resolution optical coherence tomography becomes pivotal.

The American Academy of Ophthalmology will hold its annual meeting beginning Friday at McCormick Place in Chicago.

According to one study, when genetic testing is coupled with advanced imaging, the chances of identifying keratoconus early are greater.

The authors noted that the proportion of patients losing fewer than 15 letters from the baseline BCVA score in the study eye was comparable between the ranibizumab and biosimilar treatment groups.

According to Nicole Fram, MD, around the world, corneal specialists are making the most of limited resources.

According to Nicox SA, the patients made their final 3-month visit last week. Top line results of the trial are expected in November.

The Florida Second District Court of Appeal has renewed a woman’s lawsuit claiming she suffered permanent eye damage when her ophthalmologist misdiagnosed her during nasal surgery. In its opinion, the appellate court ruled that the trial court erred when it dismissed the lawsuit.

This research team conducted a cross-sectional multicenter study to report the ocular fundus manifestations in infants with congenital ZIKV exposure in French Guiana, Martinique, and Guadeloupe, French West Indies.

Recent reports of retinal atrophy have raised concerns on potential long-term safety.

The advanced swept-source OCT technology allows visualization of the variations in the normal changes and those associated with aging in the posterior vitreous.

The treatment of vision problems can help improve the quality of life for many people in the city.

Fluocinolone acetonide intravitreal implant or faricimab (6.0 mg) injections versus observation will be studied for the prevention of visual acuity loss due to radiation retinopathy

Jeremy Tan, MD, discusses the latest trends in eye trauma surgery at the Dean McGee Eye Institute.

Coherus BioSciences’ ranibizumab-eqrn is the first and only FDA-approved biosimilar interchangeable with ranibizumab injection for all indications, with 12 months of interchangeability exclusivity.

NYU Langone Health has been recognized as No. 1 in quality and safety for inpatient and ambulatory care by Vizient Inc.

The investigators emphasized that hydroxychloroquine doses of 5 mg/kg/day or less, in accordance with current ophthalmology and rheumatology guidelines, was associated with a higher risk of lupus flares, and the threshold was near 5 mg/kg/day.

Co-chairs Peter J. McDonnell, MD, director of the Wilmer Eye Institute at Johns Hopkins University School of Medicine in Baltimore, Maryland, and Oluwatosin U. Smith, MD, of Glaucoma Associates of Texas in Dallas break down the top reasons to attend this year's Ophthalmology Times® EyeCon 2022 in a series of video segments.

Provectus will have an exclusive worldwide license of intellectual property developed by the Ophthalmic Biophysics Center of the Bascom Palmer Eye Institute.

The clinical trial is examining the efficacy of two doses of UBX1325 compared to every other month treatment with aflibercept through 24 weeks.

The authors noted that the proportion of patients losing fewer than 15 letters from the baseline BCVA score in the study eye was comparable between the two groups.

Investigators have reported good progress in determining how the disease works in the eye; however, a downside is the inflammation that seems to accompany treatment with increased dosing.

The clinical trial is examining the efficacy of two doses of UBX1325 compared to every other month treatment with aflibercept through 24 weeks.

A powerful conversation about expectations can open communication and trust.